LBA3 Transarterial chemoembolization (TACE) with or without lenvatinib (len) + pembrolizumab (pembro) for intermediate-stage hepatocellular carcinoma (HCC): Phase III LEAP-012 study

作者：J. Llovet, R.S. Finn, Z. Ren, Yiying Guo, Guiyan Han, Haiyan Lin, Jie Zheng, Sadahisa Ogasawara, H. Li, Jeong Ho Kim, Huanyu Zhao, C. Li, David C. Madoff, R. Mark Ghobrial, Anthony B. El-Khoueiry, Arndt Vogel, Xiao‐Xia Peng, K. Mody, L. Dubrovsky, M. Kudo · 发表于：Annals of Oncology · 年份：2024 · DOI：10.1016/j.annonc.2024.08.2277 · 被引用次数：32 · 研究领域：Hepatocellular Carcinoma Treatment and Prognosis、Liver Disease Diagnosis and Treatment、Liver physiology and pathology